Detailed Mechanism Funding and Narrative

Years of mechanism: 2013 2014 2015 2016 2017 2018

Details for Mechanism ID: 16850
Country/Region: Nigeria
Year: 2014
Main Partner: AIDS Prevention Initiative in Nigeria, LTD
Main Partner Program: Nigeria
Organizational Type: NGO
Funding Agency: HHS/CDC
Total Funding: $20,431,131 Additional Pipeline Funding: N/A

NOTE: The following is taken from summaries released by PEPFAR on the PEPFAR Data Dashboard. They are incomplete summary paragraphs only and do not contain the full mechanism details. When the full narratives are released, we will update the mechanism pages accordingly.

APIN will implement this cooperative agreement in Lagos, Oyo and Ogun states of Nigeria. The general population will be targeted in Lagos State being PEPFAR Nigeria Tier 2 state while clients attending supported health facilities will be targeted in Oyo and Plateau States.

In line with the USG strategic focus using the tiered approach, APIN will provide interventions which include support passive enrolment of patients into treatment in Oyo and Plateau State and a strategic scale up of PMTCT services in Lagos State. APIN’s community programs will be maintained in Lagos State and transitioned in Oyo and Plateau State. Support for FBC, Chemistry, Chest X-ray, Hep B Ag testing and VDRL will be transitioned.

APIN will support service integration and linkages between the facilities and communities to ensure a continuum of care and improving patient enrolment and retention, and enhancing the quality of service provision.

As part of its lead implementing partner role, APIN will continue to promote health systems strengthening and support efficient planning, integration into broad health services, resource leveraging and capacity building, thereby contributing to country ownership and sustainability of the program. This will involve governments at all levels, partner sites, community structures, faith-based organizations etc. The State Implementation Team (SIT) and LGA Implementation Teams (LIT) in each state will continue to be supported to effectively carry out their oversight functions. APIN will promote joint program planning, implementation and monitoring/supervision of the program with relevant government agencies and other stakeholders, and actively participate in National/State TWG meetings.

Mechanism Allocation by Budget Code for Selected Year
Care: Adult Care and Support (HBHC) $2,787,363
Care: Orphans and Vulnerable Children (HKID) $1,418,109
Care: TB/HIV (HVTB) $688,243
Care: Pediatric Care and Support (PDCS) $167,346
Laboratory Infrastructure (HLAB) $2,166,910
Strategic Information (HVSI) $90,000
Biomedical Prevention: Blood Safety (HMBL) $34,502
Biomedical Prevention: Injection Safety (HMIN) $119,874
Sexual Prevention: Abstinence/Be Faithful (HVAB) $0
Testing: HIV Testing and Counseling (HVCT) $1,244,288
Sexual Prevention: Other Sexual Prevention (HVOP) $1,467,827
Biomedical Prevention: Prevention of Mother to Child Transmission (MTCT) $1,783,006
Treatment: Adult Treatment (HTXS) $7,981,012
Treatment: Pediatric Treatment (PDTX) $482,651
Mechanism Target Information

Since COP2014, PEPFAR no longer produces narratives for every mechanism it funds. However, PEPFAR has now included performance targets or indicator information for each mechanism based on the Monitoring, Evaluation, and Reporting (MER) system. The MER guidance is available on PEPFAR's website https://www.pepfar.gov/reports/guidance/. Note that COP years 2014-2015 were under a previous version of the MER system and the indicators and definitions may have changed as of the new 2.0 guidance.

MER Indicator MER description Target Fiscal Year Target
BS_COLL By: Number of whole blood donations screened for HIV in an NBTS ne2rk laboratory 2015 23,400
BS_COLL By: Number of whole blood donations screened for HIV in an NBTS ne2rk laboratory that are identified as reactive for HIV 2015 520
BS_COLL Number of whole blood collections each year by the NBTS ne2rk 2015 26,000
GEND_GBV Age: 0-9 2015 18
GEND_GBV Age: 10-14 2015 35
GEND_GBV Age: 15-17 2015 53
GEND_GBV Age: 18-24 2015 31
GEND_GBV Age: 25+ 2015 15
GEND_GBV By PEP service provision (related to sexual violence services provided) 2015 118
GEND_GBV By type of service: Physical and/or Emotional Violence (Other Post-GBV Care) 2015 34
GEND_GBV By type of service: Sexual Violence (Post-Rape Care) 2015 118
GEND_GBV Number of people receiving post-GBV care 2015 152
GEND_GBV Sex: Female 2015 101
GEND_GBV Sex: Male 2015 51
GEND_GBV Sum of Age disaggregates 2015 152
GEND_GBV Sum of Sex disaggregates 2015 152
HTS_TST Age/sex: <1 Female 2015 2,707
HTS_TST Age/sex: <1 Female 2015 2,707
HTS_TST Age/sex: <1 Male 2015 2,601
HTS_TST Age/sex: <1 Male 2015 2,601
HTS_TST Age/sex: 1-4 Female 2015 2,365
HTS_TST Age/sex: 1-4 Female 2015 2,365
HTS_TST Age/sex: 1-4 Male 2015 2,258
HTS_TST Age/sex: 1-4 Male 2015 2,258
HTS_TST Age/sex: 10-14 Female 2015 2,097
HTS_TST Age/sex: 10-14 Female 2015 2,097
HTS_TST Age/sex: 10-14 Male 2015 2,043
HTS_TST Age/sex: 10-14 Male 2015 2,043
HTS_TST Age/sex: 15-19 Female 2015 42,020
HTS_TST Age/sex: 15-19 Female 2015 42,020
HTS_TST Age/sex: 15-19 Male 2015 22,659
HTS_TST Age/sex: 15-19 Male 2015 22,659
HTS_TST Age/sex: 20-24 Female 2015 113,283
HTS_TST Age/sex: 20-24 Female 2015 113,283
HTS_TST Age/sex: 20-24 Male 2015 46,903
HTS_TST Age/sex: 20-24 Male 2015 46,903
HTS_TST Age/sex: 25-49 Female 2015 254,628
HTS_TST Age/sex: 25-49 Female 2015 254,628
HTS_TST Age/sex: 25-49 Male 2015 147,348
HTS_TST Age/sex: 25-49 Male 2015 147,348
HTS_TST Age/sex: 5-9 Female 2015 941
HTS_TST Age/sex: 5-9 Female 2015 941
HTS_TST Age/sex: 5-9 Male 2015 914
HTS_TST Age/sex: 5-9 Male 2015 914
HTS_TST Age/sex: 50+ Female 2015 4,704
HTS_TST Age/sex: 50+ Female 2015 4,704
HTS_TST Age/sex: 50+ Male 2015 4,569
HTS_TST Age/sex: 50+ Male 2015 4,569
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female 2015 8,110
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male 2015 7,815
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female 2015 414,636
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male 2015 221,479
HTS_TST Aggregated Age/sex: <15 Female 2015 8,110
HTS_TST Aggregated Age/sex: <15 Male 2015 7,815
HTS_TST Aggregated Age/sex: 15+ Female 2015 414,636
HTS_TST Aggregated Age/sex: 15+ Male 2015 221,479
HTS_TST By Test Result: Negative 2015 634,664
HTS_TST By Test Result: Negative 2015 634,664
HTS_TST Number of individuals who received T&C services for HIV and received their test results during the past 12 months 2015 652,040
HTS_TST Number of individuals who received T&C services for HIV and received their test results during the past 12 months 2015 652,040
HTS_TST Sum of Age/Sex disaggregates 2015 652,040
HTS_TST Sum of Age/Sex disaggregates 2015 652,040
HTS_TST Sum of Aggregated Age/Sex <15 2015 15,925
HTS_TST Sum of Aggregated Age/Sex <15 2015 15,925
HTS_TST Sum of Aggregated Age/Sex 15+ 2015 636,115
HTS_TST Sum of Aggregated Age/Sex 15+ 2015 636,115
HTS_TST Sum of Aggregated Age/Sex disaggregates 2015 652,040
HTS_TST Sum of Aggregated Age/Sex disaggregates 2015 652,040
HTS_TST Sum of Test Result disaggregates 2015 652,040
HTS_TST Sum of Test Result disaggregates 2015 652,040
HTS_TST_POS By Test Result: Positive 2015 17,376
HTS_TST_POS By Test Result: Positive 2015 17,376
LAB_ACC By site support type: Direct Service Delivery (DSD) 2015 7
LAB_ACC Number of PEPFAR-supported testing facilities (laboratories) that are recognized by national, regional, or international standards for accreditation or have achieved a minimal acceptable level towards attainment of such accreditation 2015 7
LAB_ACC Sum of Support Type disaggregates 2015 7
LAB_CAP By clinical laboratories 2015 35
LAB_CAP By site support type: Direct Service Delivery (DSD) 2015 35
LAB_CAP Number of PEPFAR-supported testing facilities with capacity to perform clinical laboratory tests 2015 35
LAB_CAP Sum of Site Support Type disaggregates 2015 35
LAB_PT CD4: Number of laboratories that achieve acceptable successful passing criteria in this PT program 2015 70
LAB_PT CD4: Number of laboratories that participate in this PT program 2015 70
LAB_PT CD4: Number of laboratories that perform this testing 2015 1
LAB_PT Early infant diagnostics: Number of laboratories that achieve acceptable successful passing criteria in this PT program 2015 1
LAB_PT Early infant diagnostics: Number of laboratories that participate in this PT program 2015 1
LAB_PT Early infant diagnostics: Number of laboratories that perform this testing 2015 1
LAB_PT HIV serologic/diagnostic testing: Number of laboratories that achieve acceptable successful passing criteria in this PT program 2015 60
LAB_PT HIV serologic/diagnostic testing: Number of laboratories that participate in this PT program 2015 70
LAB_PT HIV serologic/diagnostic testing: Number of laboratories that perform this testing 2015 1
LAB_PT HIV viral load: Number of laboratories that achieve acceptable successful passing criteria in this PT program 2015 1
LAB_PT HIV viral load: Number of laboratories that participate in this PT program 2015 1
LAB_PT HIV viral load: Number of laboratories that perform this testing 2015 1
LAB_PT TB diagnostics (AFB microscopy, Xpert MTB/RIF, Culture/DST): Number of laboratories that achieve acceptable successful passing criteria in this PT program 2015 70
LAB_PT TB diagnostics (AFB microscopy, Xpert MTB/RIF, Culture/DST): Number of laboratories that participate in this PT program 2015 70
LAB_PT TB diagnostics (AFB microscopy, Xpert MTB/RIF, Culture/DST): Number of laboratories that perform this testing 2015 70
OVC_ACC Age: <1 2015 880
OVC_ACC Age: 1-4 2015 3,668
OVC_ACC Age: 10-14 2015 3,521
OVC_ACC Age: 15-17 2015 2,053
OVC_ACC Age: 18+ 2015 440
OVC_ACC Age: 5-9 2015 4,108
OVC_ACC Number of active beneficiaries receiving support from PEPFAR OVC programs to access HIV services 2015 14,670
OVC_ACC Sex: Female 2015 7,482
OVC_ACC Sex: Male 2015 7,188
OVC_ACC Sum of Age disaggregates 2015 14,670
OVC_ACC Sum of Sex disaggregates 2015 14,670
OVC_SERV Age: <1 2015 2,934
OVC_SERV Age: 1-4 2015 12,225
OVC_SERV Age: 10-14 2015 11,247
OVC_SERV Age: 15-17 2015 6,846
OVC_SERV Age: 18+ 2015 1,956
OVC_SERV Age: 5-9 2015 13,692
OVC_SERV Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS 2015 48,900
OVC_SERV Sex: Female 2015 24,939
OVC_SERV Sex: Male 2015 23,961
OVC_SERV Sum of Age disaggregates 2015 48,900
OVC_SERV Sum of Sex disaggregates 2015 48,900
PMTCT_ARV Life-long ART (including Option B+) 2015 2,919
PMTCT_ARV Maternal AZT (prophylaxis component of WHO Option A during pregnancy and delivery) 2015 265
PMTCT_ARV Maternal triple ARV prophylaxis (provided with the intention to stop at the end of the breastfeeding period) 2015 2,123
PMTCT_ARV Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry) 2015 5,833
PMTCT_ARV Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery 2015 5,308
PMTCT_ARV Single-dose nevirapine (with or without tail) 2015 53
PMTCT_ARV Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy 2015 1,930
PMTCT_ARV Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy 2015 989
PMTCT_ARV Sum of New and Current disaggregates 2015 2,919
PMTCT_ARV Sum of Regimen Type disaggregates 2015 5,360
PMTCT_ARV_NGI Life-long ART (including Option B+) 2015 2,919
PMTCT_ARV_NGI Maternal AZT (prophylaxis component of WHO Option A during pregnancy and delivery) 2015 265
PMTCT_ARV_NGI Maternal triple ARV prophylaxis (provided with the intention to stop at the end of the breastfeeding period) 2015 2,123
PMTCT_ARV_NGI Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry) 2015 5,833
PMTCT_ARV_NGI Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery 2015 5,308
PMTCT_ARV_NGI Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy 2015 1,933
PMTCT_ARV_NGI Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy 2015 989
PMTCT_ARV_NGI Sum of New and Current disaggregates 2015 2,922
PMTCT_ARV_NGI Sum of Regimen disaggregates 2015 5,307
PMTCT_EID By infants who received a virologic test within 2 months of birth 2015 1,752
PMTCT_EID By infants who received their first virologic HIV test between 2 and 12 months of age 2015 3,556
PMTCT_EID By infants with a positive virologic test result within 12 months of birth 2015 265
PMTCT_EID Number of HIV- positive pregnant women identified during the reporting period (include known HIV-positive women at entry into PMTCT) 2015 6,032
PMTCT_EID Number of infants who had a virologic HIV test within 12 months of birth during the reporting period 2015 5,308
PMTCT_EID Sum of Infant Age disaggregates 2015 5,308
PMTCT_STAT By: Known positives at entry 2015 2,333
PMTCT_STAT By: Number of new positives identified 2015 3,500
PMTCT_STAT Number of new ANC and L&D clients 2015 204,988
PMTCT_STAT Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results) 2015 186,539
PMTCT_STAT Sum of Positives Status disaggregates 2015 5,833
PMTCT_STAT_NGI By: Known positives at entry 2015 2,333
PMTCT_STAT_NGI By: Number of new positives identified 2015 3,500
PMTCT_STAT_NGI Number of new ANC and L&D clients 2015 204,988
PMTCT_STAT_NGI Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results) 2015 186,539
PMTCT_STAT_NGI Sum of Positives Status disaggregates 2015 5,833
PP_PREV Age/sex: 10-14 Female 2015 2,500
PP_PREV Age/sex: 10-14 Male 2015 2,402
PP_PREV Age/sex: 15-19 Female 2015 3,000
PP_PREV Age/sex: 15-19 Male 2015 2,883
PP_PREV Age/sex: 20-24 Female 2015 7,501
PP_PREV Age/sex: 20-24 Male 2015 7,207
PP_PREV Age/sex: 25-49 Female 2015 11,252
PP_PREV Age/sex: 25-49 Male 2015 10,811
PP_PREV Age/sex: 50+ Female 2015 750
PP_PREV Age/sex: 50+ Male 2015 721
PP_PREV Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period 2015 49,027
PP_PREV Sum of Age/Sex disaggregates 2015 49,027
PP_PREV Total number of people in the target population 2015 178,119
QI_SITE By site support type: Direct Service Delivery (DSD): Number of PEPFAR-supported clinical service sites with a quality improvement activity completed that addresses clinical HIV programs and has documented results in the last 6 months 2015 86
QI_SITE By site support type: Direct Service Delivery (DSD): Total number of PEPFAR-supported sites for any HIV clinical service including HIV Care, HIV Treatment, TB care, PMTCT, VMMC, HTC 2015 120
QI_SITE Number of PEPFAR-supported clinical service sites with a quality improvement activity completed that addresses clinical HIV programs and has documented process results in the last 6 months 2015 86
QI_SITE Sum of Numerator Site Support Type disaggregates 2015 86
QI_SITE Total number of PEPFAR-supported sites for any HIV clinical service including HIV Care, HIV Treatment, TB care, PMTCT, VMMC, and HTC 2015 120
QI_SITE_den Sum of Denominator Site Support Type disaggregates 2015 120
TB_ART The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period 2015 1,685
TB_SCREEN Age: <1 2015 1,766
TB_SCREEN Age: 1-4 2015 1,288
TB_SCREEN Age: 10-14 2015 379
TB_SCREEN Age: 15-19 2015 7,578
TB_SCREEN Age: 20-24 2015 11,367
TB_SCREEN Age: 25-49 2015 49,255
TB_SCREEN Age: 5-9 2015 606
TB_SCREEN Age: 50+ 2015 3,539
TB_SCREEN Aggregated Age - USE WITH HQ PERMISSION ONLY: <15 2015 4,039
TB_SCREEN Aggregated Age - USE WITH HQ PERMISSION ONLY: 15+ 2015 71,739
TB_SCREEN Sex: Female 2015 53,045
TB_SCREEN Sex: Male 2015 22,733
TB_SCREEN Sum of Age disaggregates 2015 11,617
TB_SCREEN Sum of Aggregated Age disaggregates 2015 75,778
TB_SCREEN Sum of Sex disaggregates 2015 75,778
TB_SCREEN The number of PLHIV who were screened for TB symptoms at the last clinical visit to an HIV care facility during the reporting period 2015 75,778
TX_CURR Age/Sex: <1 Female 2015 120
TX_CURR Age/Sex: <1 Male 2015 135
TX_CURR Age/Sex: 1-4 Female 2015 565
TX_CURR Age/Sex: 1-4 Male 2015 637
TX_CURR Age/Sex: 15+ Female 2015 43,312
TX_CURR Age/Sex: 15+ Male 2015 21,333
TX_CURR Age/Sex: 5-14 Female 2015 1,026
TX_CURR Age/Sex: 5-14 Male 2015 1,158
TX_CURR Aggregated Age/Sex: <1 Female 2015 120
TX_CURR Aggregated Age/Sex: <1 Male 2015 135
TX_CURR Aggregated Age/Sex: <15 Female 2015 1,711
TX_CURR Aggregated Age/Sex: <15 Male 2015 1,929
TX_CURR Aggregated Age/Sex: 15+ Female 2015 43,313
TX_CURR Aggregated Age/Sex: 15+ Male 2015 21,333
TX_CURR Number of adults and children receiving antiretroviral therapy (ART) 2015 68,286
TX_CURR Percent children with advanced HIV infection receiving antiretroviral therapy (ART) [CURRENT] 2015 5
TX_CURR Percent women and girls with advanced HIV infection receiving antiretroviral therapy (ART) [CURRENT] 2015 66
TX_CURR Sum of age/sex disaggregates 2015 3,641
TX_CURR Sum of Aggregated Age/Sex <15 2015 3,640
TX_CURR Sum of Aggregated Age/Sex 15+ 2015 64,646
TX_CURR Sum of Aggregated Age/Sex disaggregates 2015 68,286
TX_CURR_NGI Age/Sex: <1 Female 2015 120
TX_CURR_NGI Age/Sex: <1 Male 2015 135
TX_CURR_NGI Age/Sex: 1-4 Female 2015 565
TX_CURR_NGI Age/Sex: 1-4 Male 2015 637
TX_CURR_NGI Age/Sex: 15+ Female 2015 43,312
TX_CURR_NGI Age/Sex: 15+ Male 2015 21,333
TX_CURR_NGI Age/Sex: 5-14 Female 2015 1,026
TX_CURR_NGI Age/Sex: 5-14 Male 2015 1,158
TX_CURR_NGI Aggregated Age/Sex: <1 Female 2015 120
TX_CURR_NGI Aggregated Age/Sex: <1 Male 2015 135
TX_CURR_NGI Aggregated Age/Sex: <15 Female 2015 1,711
TX_CURR_NGI Aggregated Age/Sex: <15 Male 2015 1,929
TX_CURR_NGI Aggregated Age/Sex: 15+ Female 2015 43,313
TX_CURR_NGI Aggregated Age/Sex: 15+ Male 2015 21,333
TX_CURR_NGI Number of adults and children receiving antiretroviral therapy (ART) 2015 68,286
TX_CURR_NGI Sum of Age/Sex disaggregates 2015 68,286
TX_CURR_NGI Sum of Aggregated Age/Sex <15 2015 3,640
TX_CURR_NGI Sum of Aggregated Age/Sex 15+ 2015 64,646
TX_CURR_NGI Sum of Aggregated Age/Sex disaggregates 2015 68,286
TX_NEW Aggregated Grouping by Age: <1 Male 2015 75
TX_NEW Aggregated Grouping by Age/Sex: <1 Female 2015 71
TX_NEW Aggregated Grouping by Age/Sex: <15 Female 2015 477
TX_NEW Aggregated Grouping by Age/Sex: <15 Male 2015 537
TX_NEW Aggregated Grouping by Age/Sex: 15+ Female 2015 12,424
TX_NEW Aggregated Grouping by Age/Sex: 15+ Male 2015 5,582
TX_NEW Breastfeeding status 2015 630
TX_NEW By Age/Sex: <1 Female 2015 71
TX_NEW By Age/Sex: <1 Male 2015 75
TX_NEW By Age/Sex: 1-4 Female 2015 95
TX_NEW By Age/Sex: 1-4 Male 2015 107
TX_NEW By Age/Sex: 10-14 Female 2015 191
TX_NEW By Age/Sex: 10-14 Male 2015 220
TX_NEW By Age/Sex: 15-19 Female 2015 1,864
TX_NEW By Age/Sex: 15-19 Male 2015 837
TX_NEW By Age/Sex: 20-24 Female 2015 3,106
TX_NEW By Age/Sex: 20-24 Male 2015 1,395
TX_NEW By Age/Sex: 25-49 Female 2015 4,971
TX_NEW By Age/Sex: 25-49 Male 2015 2,233
TX_NEW By Age/Sex: 5-9 Female 2015 119
TX_NEW By Age/Sex: 5-9 Male 2015 134
TX_NEW By Age/Sex: 50+ Female 2015 2,485
TX_NEW By Age/Sex: 50+ Male 2015 1,116
TX_NEW Number of adults and children newly enrolled on antiretroviral therapy (ART) 2015 19,019
TX_NEW Pregnancy status 2015 994
TX_NEW Sum of Age/Sex disaggregates 2015 19,019
TX_NEW Sum of Aggregated Age/Sex disaggregates 2015 19,020
TX_RET Age: 0-4 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2015 284
TX_RET Age: 15+ (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2015 13,476
TX_RET Age: 5-14 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2015 426
TX_RET Aggregated Age: <15 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2015 709
TX_RET Aggregated Age: 15+ (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2015 13,476
TX_RET Number of adults and children who are still alive and on treatment at 12 months after initiating ART 2015 14,186
TX_RET Pregnancy and breastfeeding status (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2015 6,667
TX_RET Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up 2015 16,689
TX_RET_den Age: 0-4 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2015 334
TX_RET_den Age: 15+ (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2015 15,855
TX_RET_den Age: 5-14 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2015 501
TX_RET_den Aggregated Age: <15 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2015 834
TX_RET_den Aggregated Age: 15+ (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2015 15,855
TX_RET_den Pregnancy and breastfeeding status (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2015 784
Cross Cutting Budget Categories and Known Amounts Total: $1,073,822
Gender: Gender Based Violence (GBV) $300,000
GBV Prevention
Capacity building
Post GBV Care
Monitoring and Evaluation
Motor Vehicles: Purchased $230,833
Condoms: Policy, Tools, and Services $542,989
Key Issues Identified in Mechanism
Tuberculosis
Family Planning